Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma

Lenvatinib, an oral small-molecule multiple tyrosine kinase inhibitor (TKI), has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC). Proteinuria is one of the most common adverse events associated with lenvatinib treatment. We reported a 67-year-old Thai female was...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasoppokakorn, Thaninee, Thanapirom, Kessarin, Treeprasertsuk, Sombat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467805/
https://www.ncbi.nlm.nih.gov/pubmed/36106338
http://dx.doi.org/10.1155/2022/5101856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467805/
https://www.ncbi.nlm.nih.gov/pubmed/36106338
http://dx.doi.org/10.1155/2022/5101856

Ejemplares similares